Although there is significant differentiation in the scientific rationale and clinical prospects across these first-in-class products, the majority of first-in-class targets demonstrate significant preclinical evidence, and alignment to molecular pathophysiological changes. Scope – Analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing. – A brief introduction to chronic and acute pain, including subtypes, symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms. – The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline. – Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target. – Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets. – Assessment of the licensing and co-development deal landscape for pain therapeutics, and benchmarking of deals involving first-in-class versus non-first-in-class-products. Reasons to buy – Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis. – Visualize the composition of the pain markets in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/frontier-pharma-chronic-acute-neuropathic-005700175.html
The treatment depends on the underlying causes. Physical Therapy: As the pain goes down, physical therapy and muscle strengthening exercises play a major role in faster recovery. Tests like urinalysis, ECG, blood tests, etc., can help detect serious health problems, if any, due to which the swelling must have occurred. The most common cause of swollen ankles, accompanied with pain, can be a sprain, an injury caused to the ligament that connects bones with each other, as a result of abnormal pressure exerted at an unnatural angle on the foot. Shoes that are too tight can make the ankle red and painful. However, there can be injuries that are more severe, such as high ankle sprains, which can be more difficult to treat and could require surgery. read what he saidAs mentioned earlier, an accidental twist of the ankle may dislodge the bone or overstretch the muscles causing intense pain. Other prescription medications for swollen ankle treatment include pain relievers and antibiotics. It is difficult for you to exert pressure on the leg. Following the instructions of the doctor, like mild exercises, healthy diet and the prescribed medications, will certainly prove to be a great help in the recovery process.
— Washington Redskins corner Bashaud Breeland suffered an injury to his left ankle on the second possession and will miss the remainder of Sunday’s game. Additionally, safety DeAngelo Hall is out with a right knee sprain. contentHall initially said his ACL was torn, but he is getting an MRI in the morning and appeared to be walking okay in the locker room. Redskins cornerback Bashaud Breeland is carted off the MetLife field after he suffered an ankle injury during the first quarter against the Giants on Sunday. Brad Penner/USA TODAY Sports The loss is a big blow to Washington’s defensive game plan and has already had an impact. Breeland was mostly going to cover rookie Sterling Shepard in the slot with veterans Josh Norman and Greg Toler outside. Minus Breeland, Dashaun Phillips entered and allowed a touchdown pass to Shepard. Breeland, who wore a protective walking boot on his right foot and needed crutches, said X-rays on his ankle were negative, but he will undergo an MRI Monday morning. So, too, will right guard Shawn Lauvao, who also exited wearing a walking boot. Center Kory Lichtensteiger injured his calf and left the game early in the third quarter.
For the original version including any supplementary images or video, visit http://www.espn.com/nfl/story/_/id/17634317/washington-redskins-lose-bashaud-breeland-deangelo-hall-injuries
You may also be interested to read
- get redirected here
- he said
- useful link